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57 ABSTRACT 
An auxiliary substance such as a label, support, or bi 
oactive agent is attached to a protein at a site that is 
remote from the active site of the protein by the use of 
exopeptidase and a nucleophile which is an amino acid, 
amino acid derivative, amine or alcohol. In one embodi 
ment, the nucleophile is attached to the carboxy termi 
nus of a protein by catalysis with exopeptidase to form 
an adduct and then the adduct or its combination with 
a linker arm is bound to the auxiliary substance. In 
another embodiment, the auxiliary substance or its com 
bination with a linker arm is bound to the nucleophile to 
form an intermediate substance which is then coupled by catalysis with exopeptidase to the carboxy terminus 
of a protein. 
7 Claims, 2 Drawing Sheets 
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EXOPEPTDASE CATALYZED STE SPECIFIC 
BONDING OF SUPPORTS, LABELS AND 
BOACTIVE AGENTS TO PROTENS 
CROSS-REFERENCE TO RELATED 
APPLICATION 
This application is a continuation-in-part of U.S. pa 
tent application Ser. No. 07/375,138, filed Jun. 30, 1989. 
TECHNICAL FIELD 
This invention relates to immobilized and labeled 
proteins and to the attachment of proteins to bioactive 
agents. Specifically, it relates to methods for attaching 
labels, immobilization supports and bioactive agents to 
specific sites of proteins. 
BACKGROUND OF THE INVENTION 
It is well-known that the function of bioactive prote 
ins can often be enhanced by their combination with 
other substances. When used to catalyze a reaction or to 
obtain separation, proteins can be immobilized to in 
crease reaction efficiency and simplify the processing. 
When used as detecting agents, proteins can be labeled 
to facilitate measurement. When used to complex with 
or treat biological organisms, proteins can be combined 
with bioactive agents (hereinafter called "augmenta 
tion') to help achieve treatment efficacy. 
Methods for immobilizing proteins are desirable be 
cause they localize reaction sites and improve economic 
recovery. Moreover, immobilized proteins are gener 
ally less susceptible to the loss of activity due to chemi 
cal attack and changes in temperature and pH than are 
free proteins. 
Methods for labeling or augmenting proteins are 
desirable because they facilitate quantification, localiza 
tion, specificity and reactivity of the protein. The result 
ing combinations, moreover, are the resulting combina 
tions and/or powerful tools for clinical analysis and 
treatment. 
Numerous techniques exist for protein immobiliza 
tion on solid supports. Proteins can be physically ad 
sorbed onto inert supports or can be covalently bound 
to the support through reaction with bifunctional linker 
arms. Microencapsulation, gel entrapment and com 
plexation (with ion exchange resins) also can bind and 
immobilize. 
Numerous techniques also exist for binding labels and 
bioactive agents to proteins. Most of these techniques 
call for reaction of the label or agent and a functional 
group of the protein, such as an amino group, which 
occurs repeatedly throughout the protein. Although 
some repetitions of such a group are shielded from 
binding by the conformation of the protein, many others 
are exposed and available for binding with the labeling 
group or bioactive agent. The result is a mixture of 
proteins having labels or bioactive agents attached at 
various nonspecific sites. 
With any of these techniques for immobilizing, label 
ing or augmenting, several criteria should be met. The 
first is a correct spatial orientation for optimum reactiv 
ity of the proteins. A protein functions best when it is 
bound in a fashion that orients its active sites away from 
the support, label or bioactive agent and renders the 
sites available for functional operation. The second is 
the exhibition of protein activities and specificities that 
are at least comparable to those exhibited by the un 
bound form of the protein. The third, which is espe 
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cially applicable to immobilization, is the capability for 
repeated use and for a high packing density. The fourth 
is the avoidance of attachment of the support, label or 
agent within or in the vicinity of the active site of the 
protein. Otherwise, the resulting loss of functional ca 
pacity often causes inadequate reactivity and the need 
to use more protein. 
One of the most important protein embodiments 
being investigated today is the antibody. The need to 
minimize the attachment of immobilizing supports, la 
beling groups or bioactive agents within or near the 
antigen-binding site of an antibody is widely recog 
nized. 
One method for such minimization involves binding 
antigen to the antibody prior to reaction with the label 
ing group, bioactive agent, or immobilizing support. In 
this manner, the antigen shields the antibody binding 
site from reaction. The success of this shielding method, 
however, is limited. Although a high affinity of the 
antibody for the antigen exists, the equilibrium between 
the antibody/antigen complex and the free an 
tibody/antigen enables free antibody to react. This has 
foreseeable negative consequences. In addition, expo 
sure of the antigen to a labeling group, bioactive agent, 
or immobilizing support often results in attachment of 
that material to the antigen. 
The known methods for immobilizing, labeling or 
augmenting any kind of protein fall far short of main 
taining the functional capacity of the protein. Protein 
reactivity is generally lessened. Proper spatial orienta 
tion and packing density are often lacking. And, as a 
result, many attendant economic, toxic, reactive and 
non-specificity problems occur. Consequently, better 
and more specific methods for binding labels, supports 
or bioactive agents to proteins are needed. 
It is an object of the invention, therefore, to develop 
methods for labeling, immobilizing or bioactively aug 
menting proteins at sites remote from the functionally 
active site or sites of the protein. It is also an object of 
the invention to immobilize proteins by covalently bind 
ing them to an inert immobilization support. Another 
object of the invention is to covalently bind a label to a 
specific site of a protein. Another object is to covalently 
bind bioactive agents to a specific location on a protein. 
A further object of the invention is to immobilize prote 
ins so that they have the correct spatial orientation and 
packing density which will allow unhindered access to 
the functionally active site. 
SUMMARY OF THE INVENTION 
These and other objects are achieved by the present 
invention which is directed to methods for immobiliz 
ing, labeling and augmenting proteins. Generally, the 
method involves binding the immobilization support, 
label or bioactive agent (hereinafter called "auxiliary 
substance') to a protein at a specific site so that interfer 
ence with the function and performance of the protein is 
minimized or eliminated. Preferably, this specific site is 
highly remote from the active sites of the protein. 
In particular, the method of the invention involves 
two primary reactions. The first (hereinafter called the 
"primary coupling reaction"), catalytically couples an 
amino acid, an amino acid derivative, an amine or an 
alcohol (hereinafter called "nucleophile"), to the car 
boxy terminus of the protein through the use of an 
exopeptidase enzyme. The second (hereinafter called 
the "primary binding reaction'), binds the side chain of 
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the nucleophile to a specifically reactive group attached 
to the auxiliary substance. 
The method of the invention can be practiced by 
alternative synthetic routes depending on whether the 
primary coupling reaction or primary binding reaction 
is conducted first. These two routes are depicted in the 
scheme presented in the following section entitled De 
tailed Description of the Invention. 
The first synthetic route can be employed with all 
sizes and solubilities of reactants. A nucleophile having 
a distinctive side chain is first coupled to the carboxy or 
carboxy ester terminus of the protein by the primary 
coupling reaction. This coupling either adds the nucleo 
phile to the carboxy terminus of the protein (condensa 
tion) or substitutes the nucleophile for the amino acid 
residue forming that carboxy terminus (transpeptidation 
with amino acid or amine or transesterification with 
alcohol) or substitutes the nucleophile for the alcohol 
group of a terminal amino acid ester residue. The result ing protein-nucleophile adduct is then bound to an aux 
iliary substance by the primary binding reaction which 
takes advantage of the distinctive character of the side 
chain. The adduct either is directly bound to the auxil 
iary substance or is indirectly bound through a bifunc 
tional linker arm. In either case, the binding reaction 
occurs between the side chain of the nucleophile and a 
specifically reactive group on the auxiliary substance or 
linker arm. 
The second synthetic route can be employed when 
the molarities of the reactants in the reaction medium 
are sufficient to permit relatively rapid enzymatic cou 
pling. A nucleophile is first bound to the auxiliary sub 
stance by the primary binding reaction to form an inter 
mediate of the auxiliary substance and nucleophile. The 
binding can be accomplished by direct reaction of the 
side chain of the nucleophile and the auxiliary substance 
or indirectly through a linker arm that has been pre 
bound to the auxiliary substance. The intermediate is 
then coupled to the carboxy terminus of the protein by 
the primary coupling reaction. Transpeptidation, con 
densation and transesterification with amino acid, 
amino acid derivatives, amine or alcohol nucleophiles 
can all be employed in this primary coupling reaction. 
The proteins used in the method of the invention are biologically-active polypeptides. Included without limi 
tation are enzymes, enzyme inhibitors, peptide hor 
mones, DNA binding proteins, reading frame proteins, 
transcriptases, antibodies, Fabtruncated antibodies, anti body fragments, regulating proteins, peptides as small as 
two residues and various other functional proteins. 
The preferred proteins for use in the inventive 
method are monoclonal or polyclonal antibodies. Pre 
ferred classes of antibodies include those that function 
to detect antigens in biological systems or contaminants 
in biological or inanimate systems, to carry bioactive 
agents to specific sites, to diagnose disease and organic 
disfunction, to separate antigens from other materials in 
biological or inanimate systems, and to remove antigens 
from biological or inanimate systems. Especially pre 
ferred embodiments are mammalian immunoglobulin 
proteins from the IgA, Igld, IgE, IgM, or IgG class of immunoproteins. 
The amino acid nucleophile used in the method of the 
invention is an alpha amino acid or amino acid deriva 
tive having a side chain with a reactive substituent. 
Alternatively, it may have a simple, nonfunctional side 
chain in circumstances where it is also the auxiliary 
substance. When the first synthetic route is employed, 
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4. 
the side chain is chosen so that the amino acid nucleo 
phile has a distinctive character relative to the amino 
acids of the protein. With this design, the amino acid 
nucleophile rather than the amino acids of the protein is 
selectively and preferentially reacted with a specifically 
reactive group of the linker arm or auxiliary substance. 
When the second synthetic route is employed, such a 
distinctive character can be used but is not necessary 
because the primary coupling reaction provides the 
selectivity desired. 
The amine nucleophile used in the method of the 
invention mimics the amino acid nucleophile. It is a C2 
to C20 aliphatic, aromatic or arylaliphatic primary 
amine having a reactive substituent along its backbone 
or at its other terminus. The foregoing conditions re 
garding the character of the amino acid side chain also 
apply when an amine is employed in the first and second 
synthetic routes. 
The alcohol nucleophile used in the method of the 
invention is an aliphatic, aromatic or arylaliphatic C1 to 
C20 primary alcohol having a reactive substituent along 
its backbone or at its other terminus. 
The linker arm used in the method of the invention is 
a flexible or semi-flexible chain which has as its termini 
(1) a specifically reactive group that is reactive with the 
side chain of the nucleophile and (2) an other functional 
group that reacts with a combining group of the auxil 
iary substance. 
Immobilizing supports useful in the present invention 
are inorganic or organic materials which may be func 
tionalized with a specifically reactive group for selec 
tive reaction with the side chain of the nucleophile, or 
with a combining group that reacts with the other func 
tional group of the linker arm. The support is a porous 
or semiporous material that is biologically inert and 
insoluble in the medium used. 
Bioactive agents include those that act to provide a 
desirable biochemical or therapeutic result. They may 
be functionalized with a specifically reactive group for 
reaction with the side chain of the nucleophile, or with 
a combining group that reacts with the other functional 
group of the linker arm. Included are chemotherapeutic 
agents, oxidizing or reducing agents, cytotoxic agents, 
anticancer agents, radioactive agents, antibiotics, an 
timicotics, anti-infectives, heavy metal agents, antiviral 
agents, lysing agents, chelating groups and the like. 
Labels useful in the present invention include fluores 
cent groups, phosphorescent groups, colorimetric 
groups, radioactive groups, luminescent groups, spec 
trometric groups nuclear magnetic resonance groups, 
electron spin resonance groups and other groups with 
physiochemical properties that may be detected by 
measuring means. These labels may be functionalized 
with a specifically reactive group for reaction with the 
side chain of the nucleophile, or with a combining 
group that is reactive toward the other functional group 
of the linker arm. The nucleophile may also function as 
a label when it carries radioactive atoms. 
The enzymes that carry out the primary coupling 
reactions are exopeptidases. They act specifically at the 
C-terminal end of peptide chains to form or transform 
peptide bonds under basic conditions (condensation and 
transpeptidation) or acidic conditions (transesterifica 
tion) and are relatively stable under the reaction condi 
tions used. 
Preferred groups of exopeptidases for the method of 
the invention are serine carboxypeptidases. Certain of 
these enzymes, known as carboxypeptidase Y, are spe 
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cific for amino acids, or amines with neutral or basic 
side chains. Certain other classes of carboxypeptidase 
enzymes are specific for amino acids with acidic side 
chains. Correlation of the exopeptidase enzyme speci 
ficity and the neutral, acidic or basic character of the 
nucleophile to be coupled to the protein is appropriate 
according to the method of the invention. 
The conditions for the enzymatically catalyzed reac 
tion between the protein and the nucleophile include 
control of pH, temperature, concentration and incuba 
tion time. 
The present invention is also directed to methods 
which employ the labeled, immobilized or augmented protein. 
The method for use of the labeled protein involves 
combining of the labeled protein and the material upon 
which it is to act, removing any excess labeled protein 
and measuring the amount of labeled protein that has 
interacted with the material. In particular, this method 
is useful for detection of antigens or enzymatic sub 
strates/inhibitors by antibodies or enzymes, respec tively. 
The method for use of immobilized protein proceeds 
in a known manner as indicated by the character of the 
protein. The protein preferably is an enzyme, antibody, 
DNA binding protein or regulatory protein. The pre 
ferred uses will include enzymatically catalyzed reac 
tions, antibody-antigen complexations, regulation of 
reactions and DNA or enzyme separations and/or puri 
fications. One advantage of this method is the increased 
efficiency and ease of removal of the immobilized pro 
tein due to the immobilization at a specific and constant 
site remote from the reactive sites. Another advantage 
is the ability to increase the packing density of the in 
mobilized protein when all molecules are aligned in the 
same direction and have exposed active sites. 
The method for use of a bioactive agent bound to a 
protein also proceeds in a recognized manner as indi 
cated by the bioactive agent and the nature of the pro 
tein. The action of the protein and bioactive agent coop 
erate to cause the effect desired. The protein may act as 
a carrier to transport the agent across membranes or to 
cause its absorption into fluids, media or cells. It may 
also act as an absorption inhibitor to prevent transport 
of the agent across membranes or to prevent its absorp 
tion into fluids, media or cells. It may further act as a 
targeting vehicle to direct the agent to selective tissue 
sites or receptors. The advantage of this method is that 
by leaving the active sites free, the reaction efficiency 
and tissue selection are increased. 
In sum, the present invention is directed to methods 
for forming a protein bound to an auxiliary substance. 
One such method comprises the steps of (a) coupling a 
nucleophile to the protein by catalysis with an exopepti 
dase enzyme to form an adduct, wherein the nucleo 
phile is an amino acid, amino acid derivative, amine or 
alcohol having a side chain with a distinctive reactive 
substituent, and (b) binding the adduct to the auxiliary 
substance or its combination with a linker arm to form 
the bound protein, the auxiliary substance or combina 
tion having a specifically reactive group that is correla 
tively reactive toward the distinctive reactive substitu 
ent of the adduct. Another method of binding a protein 
to an auxiliary substance includes the steps of (a) bind 
ing a nucleophile to the auxiliary substance or its combi 
nation with a linker arm to form an intermediate, 
wherein the nucleophile is an amino acid, amino acid 
derivative, amine or alcohol having a side chain with a 
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reactive substituent and the auxiliary substance or com 
bination has a reactive group that is reactive toward the 
reactive substituent of the nucleophile, and (b) coupling 
the intermediate to the protein by non-neutral catalysis 
with an exopeptidase enzyme to form the bound pro 
tein. 
According to either of these two methods, the auxil 
iary substance may be an immobilization support, a label 
or a bioactive agent. It is preferred that the methods 
employ the combination of the auxiliary substance co 
valently bound to the linker arm having the specifically 
reactive functional group terminating the free end of 
the linker arm. Under basic catalysis conditions, it is 
preferred that the nucleophile is an amino acid, amino 
acid derivative or amine. Under acidic catalysis condi 
tions, it is preferred that the nucleophile is an alcohol. It 
is further preferred that catalysis conditions include a 
rapid incubation time. Amino acid nucleophiles may 
include aliphatic amino acids, hydroxy amino acids, 
sulfur-containing amino acids, diamino monocarboxylic 
acids, aromatic amino acids, heterocyclic amino acids, 
and activated derivatives thereof. It is preferred that the 
amino acid nucleophile is serine, taurine, or alanine. 
The protein in either method may be an antibody, an 
enzyme, an enzyme inhibitor, a protein hormone, a 
DNA binding protein, a regulatory protein or a DNA 
reading frame protein. It is preferred that the protein is 
a monoclonal or polyclonal antibody, and that the nu 
cleophile is substantially completely bonded to the car 
boxyl terminus of the heavy chain of the antibody. It is 
also preferred that the protein is an IgG immunopro 
tein. 
The exopeptidase enzyme may be a carboxypepti 
dase, preferably a serine or cysteine carboxypeptidase. 
The invention is also directed to methods for prepar ing a labeled protein. The methods comprise coupling a 
protein and a nucleophile of a labeled amino acid, amino 
acid derivative, amine or alcohol in a nonneutral me 
dium and in the presence of an exopeptidase enzyme. 
The label may be fluorescent, nuclear magnetic, phos 
phorescent, colorimetric, magnetic, electron resonant 
or spectrometric. One particular method according to 
the invention comprises (a) coupling a protein and a 
nucleophile in a non-neutral medium and in the pres 
ence of an exopeptidase enzyme to form an adduct, the 
nucleophile having a side chain with a distinctive reac 
tive substituent preferably selected from the group con 
sisting of sulfhydryl, hydroxyl, activated hydroxyl, 
olefinyl, activated ester, amino, azidyl, hydrazinyl, 
phosphoramidoyl, boronyl, ferrocenyl, ferro complexes 
and any mixtures thereof, (b) combining a label and a 
linker arm to form a combination, the label having at 
least one reactive group and the linker arm being a 
flexible or semi-flexible chain having a specifically reac 
tive group that is correlatively reactive with the distinc 
tive reactive substituent and another functional group 
that is reactive toward the reactive group of the label, 
and (c) binding the adduct and the combination to form 
the labeled protein. Another labeling method comprises (a) combining a label and a linker arm to form a combi 
nation, the label having at least one combining group, 
and the linker arm being a flexible or semi-flexible chain 
having a specifically reactive group that is or is ren 
dered nonreactive with the combining group of the 
label and an other functional group that is reactive 
toward the combining group of the label, (b) binding 
the combination and a nucleophile to form an intermedi 
ate, the nucleophile having a side chain with a reactive 
5,234,820 7 
substituent that is reactive toward the specifically reac 
tive group of the combination, and (c) coupling a pro 
tein and the intermediate in a non-neutral medium and 
in the presence of an exopeptidase enzyme to form the 
labeled protein. Yet another method for preparing a 
labeled protein comprises (a) binding a label and a nu 
cleophile to form an intermediate, the nucleophile hav 
ing a side chain with a reactive substituent, and the label 
having a reactive group that is reactive with the reac 
tive substituent of the nucleophile, and (b) coupling a 
protein and the intermediate in a non-neutral medium 
and in the presence of an exopeptidase enzyme. 
The resulting labeled proteins may include a protein 
having a labeled nucleophile of an amino acid, amino 
acid derivative, amine or alcohol coupled to or substi 
tuted on its carboxyl terminus. Preferably, the nucleo 
phile is substantially exclusively coupled to or substi 
tuted on the carboxy terminus. It is preferred that the 
protein is a monoclonal or polyclonal antibody, and that 
the nucleophile is serine, taurine, or alanine. It is further 
preferred that the labeled nucleophile is radioactive. 
In the protein labeling methods according to the 
invention, it is preferred that the protein concentration 
is about 1 M to about 1 mM, and the enzyme concen 
tration is from about 1 pM to mM. Under acidic cou 
pling conditions, it is preferred that the nucleophile is an 
alcohol. Under basic coupling conditions, it is preferred 
that the nucleophile is an amino acid, amino acid deriva 
tive, or amine; that the coupling reaction is conducted 
for at least 5 seconds; and that the protein, nucleophile 
and enzyme are combined in an aqueous mixture. This 
mixture may be formed by (a) combining the protein 
and the nucleophile to form a mixture, (b) adjusting the 
pH of the mixture to within a range of about 2.0 to 10.5, 
and (c) adding the enzyme to the mixture. 
The invention also provides a method for detecting 
the presence of an antigen. The method includes the 
steps of (a) combining a labeled antibody with a mate 
rial suspected of containing an antigen to form a com 
plex, the labeled antibody being specifically immunore 
active with the antigen, (b) removing any uncomplexed 
labeled antibody, and (c) measuring the amount of la 
beled antibody present in the complex. 
The invention further provides methods for prepar 
ing an immobilized protein. One such method includes 
the steps of (a) coupling a protein and a nucleophile in 
a non-neutral medium and in the presence of an exopep 
tidase enzyme to form an adduct, and (b) binding the 
adduct and an immobilization support to form the im 
mobilized protein, wherein the support has at least one 
specifically reactive group that is correlatively reactive 
toward the distinctive reactive substituent of the ad 
duct. Another method comprises (a) coupling a protein 
and a nucleophile in a non-neutral medium and in the 
presence of a exopeptidase enzyme to form an adduct, (b) combining an immobilization support and a linker 
arm to form a covalently bound combination, wherein 
the immobilization support has at least one combining 
group, and the linker arm is a flexible or semi-flexible 
chain having a specifically reactive group that is correl 
atively reactive with the distinctive reactive substituent 
of the adduct and another functional group that is reac 
tive toward the combining group of the support, and (c) 
binding the adduct and the combination to form the 
immobilized protein. According to either method, the 
nucleophile may be an amino acid, amino acid deriva 
tive, amine or alcohol having a side chain with a distinc 
tive reactive substituent, for example, a sulfhydryl, hy 
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droxyl, activated hydroxyl, amino, activated ester, 
olefinyl, azidyl, hydrazinyl, phosphoramidoyl, boronyl 
ferrocenyl, ferro complexes and any mixture thereof. 
Another method for preparing an immobilized pro 
tein according to the invention comprises (a) combining 
an immobilization support and a linker arm to form a 
covalently bound combination, the support having at 
least one combining group, and the linker arm being a 
flexible or semi-flexible chain having a specifically reac 
tive group that is or is rendered non-reactive with the 
combining group and an other functional group that is 
reactive toward the combining group of the support, (b) 
binding the combination and a nucleophile to form an 
intermediate, the nucleophile preferably being an amino 
acid, amino acid derivative, amine or alcohol having a 
side chain with a reactive substituent that is reactive 
toward the specifically reactive group of the combina 
tion, and (c) coupling the intermediate and a protein in 
a nonneutral medium and in the presence of a exopepti 
dase enzyme to form the immobilized protein. Yet an 
other method comprises the steps of (a) binding a nu 
cleophile and an immobilization support to form an 
intermediate, the nucleophile preferably being an amino 
acid, amino acid derivative, amine or alcohol having a 
side chain with a reactive substituent, and the immobili 
zation support having at least one specifically reactive 
group that is reactive toward the reactive substituent of 
the nucleophile, and (b) coupling a protein and the 
intermediate in a non-neutral medium and in the pres 
ence of an exopeptidase enzyme to form the immobi 
lized protein. 
According to any of the methods for preparing an 
immobilized protein of the invention, it is preferred that 
the carboxyl terminus of the protein is coupled to the 
support. The support may be inorganic or organic. 
Further, the support may be porous or semi-porous 
microparticles, microbeads, beads, spheres, gel parti 
cles, fibers, platelets, sheets or particulate material. 
The invention further provides methods for prepar 
ing a protein augmented by a bioactive agent. One such 
method comprises (a) coupling a protein and a nucleo 
phile in a non-neutral medium and in the presence of an 
exopeptidase enzyme to form an adduct, and (b) binding 
the adduct and a bioactive agent to form the augmented 
protein, the bioactive agent having at least one specifi 
cally reactive group that is correlatively reactive 
toward the reactive substituent of the adduct. Another 
method comprises the steps of (a) coupling a protein 
and a nucleophile in a non-neutral medium and in the 
presence of a exopeptidase enzyme to form an adduct, 
and (b) combining a bioactive agent and a linker arm to 
form covalently bound combination, the bioactive 
agent having at least one combining group, and that the 
linker arm being a flexible or semi-flexible chain having 
a specifically reactive group that is correlatively reac 
tive toward the reactive substituent of the adduct and 
an other reactive group that is reactive toward the 
combining group of the bioactive agent, and (c) binding 
the adduct and combination to form the augmented 
protein. Preferably, the nucleophile is an amino acid, 
amino acid derivative, amine or alcohol having a side 
chain with a distinctive reactive substituent selected 
from the group consisting of sulfhydryl, hydroxyl, acti 
vated hydroxyl, amino, activated ester, olefinyl, azidyl, hydrazinyl, phosphoramidoyl, boronyl ferrocenyl, 
ferro complexes and mixtures thereof, 
Another method for preparing a protein augmented 
by a bioactive agent includes (a) binding a nucleophile 
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and a bioactive agent to form an intermediate, the nu 
cleophile being an amino acid, amino acid derivative, 
amine or alcohol having a side chain with a reactive 
substituent, and the bioactive agent having at least one 
specifically reactive group that is reactive toward the 
reactive substituent of the nucleophile, and (b) coupling 
a protein and the intermediate in a non-neutral medium 
and in the presence of an exopeptodase enzyme to form 
the augmented protein. An alternative method of form 
ing an augmented protein involves (a) combining a 
bioactive agent and a linker arm to form a covalently 
bound combination, the bioactive agent having at least 
one combining group, and that the linker arm being a 
flexible or semi-flexible chain having a specifically reac 
tive group that is correlatively reactive toward the 
reactive substituent of the adduct and an other reactive 
group that is reactive toward the combining group of 
the bioactive agent, and (b) binding a nucleophile and 
the combination to form an intermediate, the nucleo 
phile being an amino acid, amino acid derivative, amine 
or alcohol having a side chain with a reactive substitu 
ent that is reactive toward the specifically reactive 
group of the combination, and (c) coupling a protein 
and the intermediate in a non-neutral medium and in the 
presence of a exopeptidase enzyme. 
According to methods for preparing an immobilized 
protein or for preparing a protein augmented by a bi 
oactive agent, it is preferred that the nucleophile is an 
amino acid, amino acid derivative or amine under basic 
coupling conditions, and an alcohol under acidic cou 
pling conditions. 
The invention also includes methods for functionally 
reacting a protein by employing an immobilized protein 
as produced according to the methods of the invention. 
Further included are methods for conducting a bioreac 
tion with a bioactive agent by employing a protein 
carrying a bioactive agent as produced according to the 
methods of the invention. 
According to the methods of the invention, it is pre 
ferred that the "distinctive reactive substituent' and 
“specifically reactive group' are selected from the fol 
lowing pairs: (a) a sulfhydryl group and a organometal 
lic group, (b) an olefinyl group and a dienyl group, (c) 
a polar olefinic group and its corresponding monomer 
or substituted forms thereof, (d) an affinity complexing 
compound and its substrate, (e) a pair of hydroborated 
olefinic groups, (f) an aromatic amino group and an 
epoxy activated ester or aldehyde group, (g) an azidyl 
or hydrazinyl group and an aromatic amino group, (h) 
an aromatic alcohol and an activated ester group, and (i) 
a hydrazine and a reducing sugar group. 
It is also preferred according to the methods of the 
invention that the linker arm chain is a polymer or 
oligomer of amide, ester, carbonate, urethane, ether, glycidyl, olefin or hydrocarbon groups, or an aliphatic 
group of from about 2 to 20 atoms, or an aromatic group 
of from about 1 to 5 rings. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1A is a graph of the pH dependence of the 
incorporation of serine in an antibody with respect to 
time at O' C. 
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FIG. 1B is a graph of the pH dependence of the in 
corporation of serine in an antibody with respect to time 
at 25' C. 
FIG. 1C is a graph of the pH dependence of the 
incorporation of serine in an antibody with respect to 
time at 37 C. 
FIG. 2 is a graphical representation of the effect of 
incubation time on serine incorporation. 
DETAILED DESCRIPTION OF THE 
INVENTION 
Until the present invention, a general method for 
highly selective, single site attachment of a auxiliary 
substance to a protein did not exist. The present meth 
ods solve this problem by providing precise control of 
the protein site to which the auxiliary substance is 
bound. This control causes the auxiliary substance to 
bind to a specific site on the protein that is as distant 
from the protein functional sites as possible, i.e. the 
carboxyl terminus. 
More specifically, the present invention is based upon 
the discovery that amino acids, amino acid derivatives, 
amines and alcohols can be coupled to the carboxyl 
termini of biologically active proteins by a condensation 
or transpeptidation reaction under basic, exopeptidase 
catalysis conditions or by a transesterification reaction 
under acidic exopeptidase catalysis conditions (the pri 
mary coupling reaction). See J.S. Fruton in "Advances 
in Enzymology', A. Meister, ed. Vol. 53, 1982, John 
Wiley & Sons New York, pp. 239-306 for a general 
review of proteinase catalyzed synthesis of peptide 
bonds, the disclosure of which is incorporated herein by 
reference. With respect to almost all functional prote 
ins, and especially antibodies, the carboxyl terminus of 
the peptide chain or chains occurs within a region of its 
three dimensional structure that is almost always re 
mote from the active site region. In antibodies, for ex 
ample, this terminus occurs within the constant region 
that is remote from the active, variable region of the 
antibody. Consequently, binding the auxiliary substance 
to the carboxy terminus of the protein provides the 
control sought. 
As described in the foregoing Summary of the Inven 
tion, the attached substance is bound to the carboxy 
terminus of the protein through either of two synthetic 
routes. In the first, the nucleophile is separately coupled 
to the protein to form an adduct of the protein and 
nucleophile. The adduct is then bound to the auxiliary 
substance directly, or is bound indirectly through a 
linker arm-auxiliary substance combination. 
In the second synthetic route, the nucleophile and 
auxiliary substance are directly bound, or indirectly 
bound through a linker arm, to form an intermediate. 
The intermediate is then coupled to the carboxy termi 
nus of the protein. 
These synthetic routes are depicted in the following 
scheme. Both synthetic routes operate in two versions, 
which depend upon whether the auxiliary substance is 
directly or indirectly bound to the nucleophile. 
Schene 
Route 
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Schene 
ProCO2H (protein) 
-- 
X-R (nucleophile) 
with enzyme 
ProCOX-R (adduct) 
-- no-o/ 
ProCOX-R-SRG-(ASub) 
ProCOX-R-SRG-(Link)-(ASub) 
N SRG-(Link)-(ASub) 
Route 2 
X-R 
-- 
SRG-(Link)-(ASub) 
N / 
X-R-SRG-(Link)-(ASub) 
-- 
ProCO2H 
with enzyme 
ProCOX-R-SRG-(Link)-(ASub) 
X-R 
-- 
SRG-(ASub) 
(protein) 
(nucleophile) 
ProCO2H is protein. R-X is the nucleophile, i.e., amino acid or aliphatic 
amine wherein R is the side chain and X is the attaching amine or hydroxy 
goup. ASub is attached substance. Link is a linker arm. SRG is specifically 
reactive group. The letter n is the number 0 and 1. Choice of X, R, SRG 
and route depend upon the functional groups of the protein and the 
solubilities of the reactants. 
Route 1 
According to route 1, the first step is the primary 
coupling reaction to form the adduct of protein and 
nucleophile. It is accomplished by exopeptidase cataly 
sis under non-neutral conditions. 
The choice of the particular amino acid, amino acid 
derivative, amine or alcohol as the nucleophile in the 
first step depends upon the identity of the amino acids of 
the protein and upon the distinctive character of the 
side chain of the nucleophile. The side chain of the 
coupled nucleophile acts as the binding site for the 
specifically reactive group of the attached substance or 
the combination of linker arm-attached substance. It has 
a structure that either is non-duplicative of the amino 
acids of the protein or is more highly reactive toward 
the specifically reactive group of the combination or 
auxiliary substance than are the amino acid side chains 
of the protein. It also is selected to avoid or minimize 
direct reaction with these side chains. 
This selectivity imposed by the nucleophile side chain 
is accomplished by its reactive substituent. This substit 
uent may be a sulfhydryl, olefinyl, amino, azidyl, hy 
drazinyl, epoxy, hydroxyl, activated hydroxy wherein 
the activator is a facile leaving group such as tosyl, 
mesyl and benzoyl, an acid group such as carboxyl, 
phosphoric or sulfonic, an activated ester such as a 
mixed anhydride, carbodiimido, iminyl amidinyl, 
imidazo, pivaloyl ester, neopentyl ester and the like, 
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ProCOX-R-SRG-(Link)-(ASub) 
phosphoramidoyl, ferrocenyl, ferro complexes, boronyl 
and similar reactive functional groups. 
In the second step of route 1, the primary binding 
reaction is accomplished by binding the nucleophile 
side chain either to the auxiliary substance or to its 
combination with the linker arm. In both of these varia 
tions, the specifically reactive group of the combination 
or auxiliary substance correlates with the reactive sub 
stituent of the side chain so that the side chain and auxil 
iary substance or combination readily react without 
substantially involving other groups of the protein. 
To accomplish this selective reactivity of the primary 
binding reaction, the reactive substituent and specifi 
cally reactive group are correlated as pairs of groups. 
Several embodiments of this pair exhibit noncompeti 
tive binding which essentially will not involve other 
groups of the protein. These include, for example: (1) a sulfhydryland an organometallic group, prefera 
bly an organomercuric group or Alman reagent 
which are particularly useful with antibodies be 
cause antibodies do not naturally contain free sulf 
hydryl groups, i.e. cysteine within or close to their 
active sites; 
(2) an olefinyl group and a dienyl group, which form 
a Diels-Alder adduct; (3) a phosphoramidoyl group and a metaliophos 
phoramidoyl or metallophosphate group, which 
form co-ordinate complexes; 
5,234,820 13 
(4) an affinity complexing compound and its corre 
sponding substrate, e.g. carbonic anhydrase and 
sulfanilamide or biotin and avidin, which form 
affinity complexes; 
(5) a ferrocenyl group or ferro complex and a mag 
netic material rendered inert to the reaction me 
dium, e.g. a teflon-coated iron wire coil, which 
form a magnetic couple; 
(6) a chelating group and a chelated moiety such as 
ethylene diamine tetraacetate and a transition 
metal, which form a chelate; 
(7) a polar olefinic or substituted olefinic group and 
the corresponding monomer, which polymerize by 
free-radical means under mild conditions, e.g. N 
acryloyl lysine and acrylamide, and form a poly 
ner; 
(8) a pair of olefinic groups, which can be hy 
droborated and then treated with silver nitrate and 
weak base to form the reduced, coupled olefin-ole 
fin adduct; and 
(9) a photoreactive arylketo group and a free radical 
stabilizing group having a radical-labile C-H 
bond; such as benzoylphenylalanine and a benzyl, 
allyl or arylalkyl group, which can be photolyzed 
to form an adduct between the keto carbon and the 
C-H carbon of the free radical stabilizing group. 
Preferably such free radical stabilizing groups as 
polyamide, polycinnamide, polystyrene, or fluo 
rene containing polymers (supports), porphyrin or 
fluorescein, (label) and benzyl substituted bioactive 
agents are employed at significantly higher concen 
trations than the protein coupled to the arylketo 
nucleophile so that photolytic addition of the pro 
tein to itself is highly disfavored (See J.C. Kauer, et 
al., J. Biol. Chenn., 261, 10695 (1986)). 
Other embodiments of this pair exhibit competitive 
binding relative to the functional groups of the protein 
but can be controlled to provide a substantially selective 
reaction of the side chain and attached substance or 
combination. These include, for example: 
(1) an aromatic amino group and an epoxy, activated 
ester or aldehyde group, preferably an aromatic 
epoxy or aldehyde group, which can be reacted to 
form a nitrogen-carbon adduct, and under slightly 
acidic conditions to protonate the amine groups of 
the protein; 
(2) an azidyl or hydrazinyl group and an aromatic 
amine, which can be reacted by irradiation with 
UV light to form a substituted amine, and under 
slightly acidic conditions to protonate the amine 
groups of the protein; 
(3) an aromatic alcohol (e.g. phenolic group) or aro 
matic amine and an activated ester, which can be 
reacted to form an ester or amide respectively, and 
under slightly acidic conditions to protonate the 
amine groups of the protein; and 
(4) a hydrazine and a reducing sugar, which form an 
OsazOne. 
The conditions and procedures for performing the 
binding reactions of the side chain and specifically reac 
tive group are known in the art. See for example "Rea 
gents for Organic Synthesis" by Fieser & Fieser, John 
Wiley & Sons, New York, Vol. I-X, 1967-1975, the 
disclosure of which is incorporated herein by reference. 
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The conditions will generally be approximately ambient 
temperatures (0 to 38 C), and dilute to moderate con 
centrations of reactants. The procedures will generally 
involve stirred reactors, removal of side products and 
slow addition of reagents. A further condition is the 
maintenance of a minimal concentration of any reactant 
that can react with more than one group in the reaction 
mixture. For example, a minimum concentration of 
auxiliary substance or combination in the binding reac 
tion is to be maintained so that the chance of undesirable 
side reactions of the specifically reactive group with the 
protein are minimized. 
Route 2 
According to route 2, the nucleophile and the auxil 
iary substance or its combination with linker arm are 
first bound by the primary binding reaction to form an 
intermediate. This step can be accomplished by employ 
ing (1) any of the reactive substituent and specifically 
reactive group pairs described above; (2) the combining 
group and other functional group pairs described below 
for the linker arm, or (3) by any of the known methods 
for forming an amide, ester, ether, imino, carbonate, 
urethane (carbamate), carbon-carbon, carbon-nitrogen, 
sulfur-carbon, sulfur-oxygen-carbon or carbon-oxygen 
bond. Methods to form these bonds and the particular 
groups formed thereby are known in the art. See, for 
example "Chemical Reagents for Protein Modifica 
tion", CRC Press Inc., R.L. Lundblad & C.M. Noyes 
ed. 1984; "Basic Principles of Organic Chemistry", J.D. 
Roberts and M. Caserio, Benjamin Press, 1975, the dis 
closures of which are incorporated herein by reference. 
Choice of the particular manner of binding the auxil 
iary substance or combination to the nucleophile does 
not depend upon the structure of the protein according 
to this route. Any stable binding group that is appropri 
ate for the chemical structures of nucleophile and auxil 
iary substance or linker arm combination will suffice 
because this binding reaction is not conducted in the 
presence of the protein. 
The second step of route 2 couples the intermediate 
to the protein through the primary coupling reaction of 
the nucleophile portion of the intermediate and the 
protein carboxy terminus. It is accomplished by exopep 
tidase catalysis under non-neutral conditions. The selec 
tivity of this reaction suits it as the one to be conducted 
in the presence of protein. The scheme of route 2 uti 
lizes this feature to best advantage because it places the 
primary coupling reaction last in the reaction sequence 
thereby eliminating the potential interference from the 
primary binding reaction. 
The second step of route 2 has some attendant param 
eters that primarily are directed to reaction efficiency. 
The reactants should have sufficient solubility in the 
reaction medium to enable relatively facile coupling to 
take place. Generally, this solubility will be preferably 
about 0.05 to 2M for the reactants and 1 to 100 LM for 
the enzyme. When the solubilities of the reactants of the 
coupling reaction are less than this, route 1 is preferen 
tially employed. 
Specific embodiments of labels, support materials and 
bioactive agents that can be coupled to proteins by 
synthetic route 2 are shown in Table 1. 
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Amino Acids for Coupling Labels, Bioactive Agents 
and Supports to Antibodies (Potential Applications are 
listed along with the chemical names of the Amino Acids) 
HOCH2CH(NH2)CO2H 
Serine Taurine 
3H, 14C 3H, 14c, 35S 
Radioactive Label Radioactive label 
H2NCH2CH2PO3H Aminoethanephosphonic 
Acid 
*H, 14c, 32p 
Radioactive Label 
31P. NMR Label 
CH2-------CH-CONHC6H4CH2CH(NH2)CO2H 
NH 
Pt 
/ N 
Cl C 
Metal Chelate 
Platinum for Electron Microscopy 
and X-ray Labels 
Cobalt for Ratiation Therapy 
fluoroescenyl NHCSNH(CH2)4CH(NH2)CO2H 
Lysylfluorenscene 
Fluoroescent Label 
(NO2)2C6H3NH(CH2)4CHONH)CO2H Bisnitrophenylysine 
Fluorescent Label 
Antigenic Label 
NH 
V 
CO-NH 
Biotin Group for Complex 
Attachment to Avidin-Resin or as 
Label for Enzymatic Detection 
Iodotyrosine Seyi 
Radioactive Label 
FC6H4CH2CH(NH2)CO2H Fluorophenylalanine 
NMR Label 
H2C=HCH2NH + CH3CH=CHCH=CHCO2-(attached substance) 
Diels-Alder 
For Attachment of Resin 
or other attached substance 
H2C=CHCONHCH2)4CH(NH2)CO2H + H2C=CHCONH-OH or attached substance) 
Free Radical Polymerization 
Magnetic Process 
Linker Arm 
There are several reasons why the linker arm version 
of routes 1 and 2 would be selected according to the 
invention. First, the environment of the carboxyl termi 
nus may prevent approach of a large, bulky auxiliary 
substance. Second, the auxiliary substance may not 
contain functional groups that are specifically reactive 
with the side chain of the nucleophile. Third, the linker 
arm increases the distance between the auxiliary sub 
stance and the protein which can help maintain the 
activity of the protein. Fourth, the protein can more 
freely adopt a spatial conformation that is appropriate 
for its reactivity. Fifth, it will lessen or minimize alter 
ation of protein confirmation caused by carrier material proximity. 
The structure of the linker arm includes functional 
groups at the ends of a flexible to semi-flexible chain. 
One of the functional groups is the specifically reactive 
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group mentioned above that reacts with the side chain 
of the nucleophile. The other functional group of the 
linker arm is chosen to readily react with available 
combining groups on the auxiliary substance. Of course, 
this pair of groups of the linker arm is selected so that 
one does not substantially interfere with the other when 
they are used in the binding and combining reactions. 
In both synthetic routes, the step to combine linker 
arm and attached substance is accomplished before the 
binding reaction with the nucleophile. Since protein 
and nucleophile are not present during this step, the 
kinds of reactions available are numerous. If the com 
bining group of the auxiliary substance is an aldehyde 
group, the other functional group may be an amine 
(Schiff base product), an activated acid such as an 
iminocarboxy, carboxyalkoxy or acid halide (amide 
product) or epoxy (substituted amine product). If the 
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combining group of the auxiliary substance is an hy 
droxy group, the other functional group may be an 
activated acid or ester (ester product) or activated alkyl 
such as a halo alkyl, alkyl tosyl or alkyl mesyl (ester 
product). If the combining group of the auxiliary sub 
stance is an acid group, the other functional group may 
be an amine (amide product) or activated hydroxyl (ester product). If the combining group of the auxiliary 
substance is a chelating agent, the other functional 
group may be a bound metal group. Other pairs of reac 
tants include water soluble carbodiimide and amino; 
N-acyl succinimide and amino; and olefin and diene as 
well as those described above under part (3) of the 
primary binding reaction for route 2. Of course, the 
reverse order of reaction is also possible. 
The backbone of the linker arm may be any that 
provides a flexible or semi-flexible chain. Included are 
polymers and oligomers of amides (peptides), olefins, 
esters, carbonates, urethanes, ethers, glycidyl, epoxides 
and the like. Also included are alkylene and hydrocar 
bon chains. The length of the backbone may be from 
about two to about 100 atoms or monomeric units, pref 
erably about four to about 20 atoms or monomeric units 
in length. Examples of the backbone include hexylenyl, 
decylenyl, poly(4-aminobutyric acid), poly(glycyl), 
poly(glycylalanyl), poly(4-hydroxybutyric acid), poly 
lactones, poly(bisphenol-A-diglycidyl ether) and poly 
acrylamide. 
Proteins 
The types of proteins (including peptides as small as 
two residues) that can be coupled according to the 
present invention are active proteins with polypeptide 
chains containing reactive carboxyl termini. Examples 
of suitable proteins include enzymes, enzyme inhibitors, 
hormones including peptide hormones, antibodies, Fab 
truncated antibodies, functional proteins, transcriptases, 
reading frame proteins, DNA binding proteins and 
other biologically active polypeptides. 
With respect to labeling, monoclonal or polyclonal 
antibodies, antibody light and heavy chains, antibody 
fragments, epitopal sites of antibodies, chimeric anti 
bodies, CDR antibodies, DNA binding proteins, en 
zymes, and reading frame proteins are preferred as pro 
teins. As used herein, the term "antibody fragments' 
includes variable or constant regions of antibody chains, 
Fab or F(ab')2 and Fc fragments, light and heavy vari 
able chains, epitopal regions of light or heavy antibody 
chains, combinations of such regions and chains, and 
recombinations of a particular fragment with a comple 
mentary fragment isolated from the same antibody or a 
different source of antibody, to form, for example, chi 
meric human-mouse antibodies carrying human con 
stant regions, or altered human antibodies carrying 
hypervariable segments derived from antibodies from a 
differing mammalian source. The antibodies and anti 
body fragments are generally useful in the diagnosis of 
diseases, disorders, or hereditary dysfunctions. The 
antibodies are also generally useful in separation tech 
niques and for detection of antigenic material. This 
includes mammalian immunoglobulin proteins from the 
IgA, Igld, IgE, IgM, or IgG class of immunoproteins. 
With respect to immobilization, mono or polyclonal 
antibodies and enzymes are preferred as proteins. 
With respect to bioactive agents, mono or polyclonal 
antibodies, peptide hormones, histocompatibility prote 
ins, polypeptide inhibitors, peptide toxins, structural 
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proteins (eg. collagen), globular proteins and fibrous 
proteins are preferred as proteins. 
Nucleophile Chosen as an Amino Acid 
A wide variety of amino acid nucleophiles can be 
used in the present invention. Generally these include 
alpha amino acids with neutral, basic or acidic side 
chains wherein the side chains may contain the reactive 
substituents mentioned above. The choice of amino acid 
for labeling antibodies, binding proteins to immobilizing 
support, or binding bioactive agents to proteins is gener 
ally coordinated with the enzyme and the protein 
chosen. Certain enzymes will couple specific amino 
acids to the carboxyl termini of proteins. For example, 
CPD-Y will generally couple amino acids with neutral 
or basic side chains to antibodies. Certain other en 
zymes, which utilize cysteine and/or serine at their 
enzymatic sites and are derived from plant and micro 
bial sources, will couple amino acids with acidic side 
chains to proteins. 
Furthermore, in order to perform the binding reac 
tion, the amino acid nucleophile will exhibit a distinc 
tive reaction character. This will allow its selective 
binding to the auxiliary substance or its combination 
with linker arm. The distinctive character results from 
the reactive substituent of the side chain of the nucleo 
phile as explained above. This reactive substituent may 
be a sulfhydryl, hydroxy, activated hydroxyl, phospora 
midoyl, hydrazinyl, amino, azidyl, epoxy, acid, boronyl, 
activated esters, ferrocentyl, ferro complex or olefinyl 
group, mixtures thereof and other functionally reactive 
groups. 
Embodiments of these amino acid nucleophiles in 
clude aliphatic amino acids such as monoamino mono 
carboxylic acids, e.g., glycine, alanine, valine, norva 
line, leucine, isoleucine, and norleucine (useful as radio 
active label); hydroxy amino acids such as serine, threo 
nine, and homoserine; sulfur-containing amino acids 
such as methionine, cystine, cysteine, and taurine (for 
linker arm or auxiliary substance binding); diamino 
monocarboxylic acids such as orthinine, lysine, and 
arginine (for linker arm or auxiliary substance binding); 
and monoamino dicarboxylic acids such as aspartic acid 
and glutamic acid (for linker arm or auxiliary substance 
binding). Also, aromatic amino acids, such as phenylala 
nine and tyrosine; heterocyclic amino acids, such as 
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histidine and tryptophan, and olefinic amino acids such 
as 2-amino-2-vinyl acetic acid (for linker arm or auxil 
iary substance binding) are included within the group of 
amino acids of the present invention. 
Additional amino acids are those with the C-terminal 
end protected. This includes, for example, amides, ani 
lides, hydrazides, esters, and the like. 
Preferred classes of amino acid nucleophile include 
aliphatic amino acids, hydroxy amino acids, their acti 
vated derivatives, phosphoramidoyl amino acids, sul 
fur-containing amino acids, diamino monocarboxylic 
acids, activated ester amino acids, aromatic amino acids 
and heterocyclic amino acids. Especially preferred em 
bodiments include serine, alanine, phenylalanine, tau 
rine, lysine, arginine, 2-aminopenta-4-enoic acid and 
cysteine. Also included are carboxyl protected amino 
acids, such as amides and esters. 
Nucleophile Chosen as an Amine 
The amine nucleophile includes any C2 to Co pri 
mary amine that has another reactive substituent along its backbone as described above. Alternatively, it may 
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have a simple, nonfunctional side chain in circum 
stances where it is also the auxiliary substance. In addi 
tion to being a decarboxy analog of the amino acid 
nucleophile, the amine nucleophile may also have a side 
chain substituted by hydroxyl, sulfhydryl, activated 
hydroxyl, epoxy, amino, azidyl, olefinyl, activated es 
ter, hydrazinyl, phosphoramidoyl, boronyl, iminyl, 
amidinyl, ferrocentyl, ferro complexes or other func 
tionally reactive groups. Alternatively, it may have a 
simple, nonfunctional side chain in circumstances where 
it is also the auxiliary substance. 
Nucleophile Chosen as an Alcohol 
The alcohol nucleophile includes any C1 to C20 pri 
mary alcohol that has another reactive substituent along 
its backbone. The reactive substituent may be a hy 
droxyl, sulfhydryl, activated hydroxyl, epoxy, amino, 
azidyl, hydrazinyl, olefinyl, activated ester, phosphora 
midoyl, boronyl, iminyl, amidinyl, ferrocentyl, ferro 
complex groups, mixtures thereof or other functionally 
reactive groups. Alternatively, it may have a simple, 
nonfunctional side chain in circumstances where it is 
also the auxiliary substance. 
Labels 
Labels for the proteins according to the present in 
vention include labeled, or tagged amino acids having a 
variety of substituents or atoms that possess properties 
suitable for detection by conventional techniques. Such 
properties include photoaffinity, magnetism, radioactiv 
ity, fluorescence, enzymatic activity, electron dense (x-ray), nuclear magnetic resonance, electron spin reso 
nance, antigenicity, and phosphorescence. For example, 
amino acids can be labeled with either C or H atoms. 
Further, the amino acids may be tagged by known fluo 
rescent dyes, porphyrins, colorimetric dyes, reactive 
groups and antigens or enzymatic substrates that permit 
spectroscopic, photographic or radiometric detection. 
See E.T. Koh, et al., Biotechniques, 7,596 et seq. (1989); 
S. Borman, "Bioconjugate Chemistry Attracts Grow 
ing Interest” in the May 8, 1989 issue of "Chemical and 
Engineering News' at p. 25 et seq., the disclosures of 
which are incorporated herein by reference. 
Enzymes 
Enzymes capable of coupling the nucleophile to the 
protein are exopeptidases, i.e., enzymes capable of act 
ing specifically at the carboxyl terminal end of peptide 
chains. See J.S. Fruton In "Advances in Enzymology', 
in the chapter entitled Reagents for Protein Modifica 
tion as cited above. They form or transform peptide 
bonds and are relatively stable under the reaction condi 
tions used. 
Carboxypeptidase enzymes are generally known to 
cleave the C-terminal peptide bond in polypeptides. 
They exhibit alternative enzymatic activities that are 
pH-dependent. For example, transpeptidation, transes 
terification and condensation products can be formed by the pH dependent action of carboxypeptidase Y. 
Preferred carboxypeptidases according to the inven 
tion include serine and cysteine (eg. hydroxy and thiol) 
carboxypeptidases. Certain of the serine and cysteine 
enzymes are capable of attaching amino acids and ali 
phatic amines with neutral or basic side chains to the 
carboxy termini of proteins. Examples of these enzymes 
include carboxypeptidase Y (CPD-Y), penicillocarbox 
ypeptidase S-1 and S-2, carboxypeptidase C and CN, 
malt carboxypeptidase I and II, phaseolin; and carboxy 
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peptidase A, carboxypeptidase B and metalloproteases, 
which perform the condensation reaction only. Certain 
other of the serine carboxypeptidase enzymes are capa 
ble of attaching amino acids and aliphatic amines having 
acidic side chains to the carboxy termini of proteins. 
Carboxypeptidase Y is a preferred enzyme for use in 
this invention. CPD-Y is an enzyme from yeast fungi 
possessing a serine residue in its catalytic site, and is 
characterized by its ability to catalyze various reactions 
depending on the pH of the reaction mixture. Further 
more, CPD-Y is a preferred enzyme for use in the label 
ing process of the present invention because it rapidly 
transpeptidates. 
It is to be understood that the enzyme may be immo 
bilized or chemically modified to retain or improve 
stability and appropriate enzymatic activity. It is also to 
be understood that the enzyme source may be yeast, 
animal, vegetable, or microbial. Enzymes produced by 
the technique of molecular cloning, either of naturally 
occurring enzymes or synthetically produced by muta 
tion or recombination, are also included in the inven 
tion. 
Immobilizing Supports 
Immobilizing supports useful in the present invention 
are inorganic or organic materials functionalized so that 
a reaction can occur between the nucleophile or linker 
arm and the support. When the former reaction is em 
ployed, the support will be functionalized with a specifi 
cally reactive group mentioned above. When the latter 
reaction is employed, the support will be functionalized 
with the combining group for the other functional 
group mentioned above. In this case also, the reactive 
substituent may be chelating ferromagnetic groups. The 
immobilizing support then has the appropriate charac 
ter to produce binding. With a ferromagnetic group, the 
support may be magnetic wire that is rendered inert to 
the reaction medium eg. with teflon. Passing a current 
through the wire will establish the magnetism needed to 
cause binding. Alternatively, a magnet external to the 
system (i.e. outside the chromatographic medium) can 
be used to cause binding to the support. With the chelat 
ing group, the support may be an immobilized metal or 
other chelate. 
The support may be a porous or semiporous solid. 
Preferably, it is biologically inert and insoluble. Materi 
als that may be used as supports include fibers, sheets, 
microspheres, particles, microparticles, beads, micro 
beads, platelets, membranes, and the like. 
The surface of the immobilizing support of the pres 
ent invention is preferably porous. The use of sub 
stances having a porous surface, such as substantially 
spherical polymeric beads or microspheres of agarose 
allows large surface areas for the attachment of protein 
at high density. A surface is considered porous where 
the size of the majority of the pores in the material is 
sufficiently large so as to allow the migration of the 
protein into the interior of the spheres. The size and 
shape of the support may be varied widely, depending 
on the particular protein and its intended use. 
The immobilizing supports include a wide variety of 
substances. The choice of support, however, depends 
upon the choice of the nucleophilic and/or linker arm as 
well as on the intended use of the immobilized protein. 
The coupling reactions, nucleophile, specifically reac 
tive group and reactive group all are compatible as 
described above. In particular, the support is chosen 
such that the nucleophile will readily couple to the 
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support or support-linker arm combination in prefer 
ence to any other reactive sites on the protein. For 
example, cysteine may be used as the amino acid nucleo 
phile to couple with a protein with no sulfhydryl groups 
eg. an antibody. A support or support-linker arm specif. 
ically reactive group is chosen that would react with 
the sulfhydryl moiety, for example, an organometallic 
group such as an organo mercury compound. Alterna 
tively, 2-amino-hex-4-enoic acid may be the amino acid 
nucleophile, and a specifically reactive group for the 
support may be one that would specifically react with 
the unsaturated side chain, as for example through a 
Diels Alder reaction. Another alternative is the choice 
of a photoaffinity label such as N-hydroxy succinimi 
dyl-4-azidosalicylic acid side chain, and an arylamine as 
the specifically reactive group on the attached sub 
stance. This salicylic side chain is to be coupled to the 
epsilon amino group of a lysine before the photo addi 
tion so that it will not be reactive with the amino groups 
of the protein. Photoreaction under, for example, u.v. 
light, will accomplish the desired photo binding reac 
tion. Moreover, if a linker arm is used, available groups 
on the support act as the reactive group. The other 
functional group of the linker arm is appropriately 
chosen to bind with the reactive group. 
Bioactive Agents 
Included within the invention is a method for attach 
ment of a bioactive agent to a protein at a site remote 
from the active site. These bioactive agents can be car 
ried or transported by the protein to a site where they 
can perform a desired reaction. 
The bioactive (biologically active) agent includes 
physiologically or pharmacologically active substances 
that act locally or systemically in the body. Examples of 
biologically active agents include peptide drugs, protein 
drugs, desensitizing agents, antigens, vaccines, anti 
infectives, antibiotics, antimicrobials, antiallergenics, 
steroidal anti-inflammatory agents, decongestants, miot 
ics, anticholinergics, sympathomimetics, sedatives, hyp 
notics, psychic energizers, tranquilizers, androgenic 
steroids, estrogens, progestational agents, humoral 
agents, prostaglandins, analgesics, antispasmodics, anti 
malarials, antihistamines, cardioactive agents, nonste 
roidal anti-inflammatory agents, antiparkinsonian 
agents, antihypertensive agents, B-adrenergic blocking 
agents, nutritional agents, metal compounds, anti-can 
cer compounds such as fluorinated nucleotides, nucleo 
tide analogs, cytosine arabinocide, 5-fluorouracil, ricin 
A, tetanus toxin, cyclic therapeutic peptides such as 
anamycin, erythromycin, cyclosporin, AZT, and alka 
loids. Also, various forms of the biologically active 
agents may be used. Forms such as uncharged mole 
cules, molecular complexes, salts, ethers, esters, and 
amides are included. 
The bioactive agents are functionalized to carry spe 
cifically reactive groups for coupling to the nucleophile 
directly. Alternatively, appropriate available combining 
groups on the bioactive agent can be reacted with the 
other functional group on a linker arm. Preferably, this 
functionalization will be accomplished with a group 
already present within the agent. 
Conditions for Primary Couplinq Reaction 
The conditions for the primary coupling reaction 
efficiently favor condensation, transpeptidation or 
transesterification over peptide cleavage. As can be 
seen from the following discussion of the application of 
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the primary coupling reaction to antibody protein, these 
conditions generally involve control of pH, tempera 
ture, reactant concentrations, enzyme concentration 
and incubation time. 
The conditions for condensation and transpeptidation 
are basic which also disfavors peptide cleavage by hy 
drolysis. They are within a pH range in which the amine 
group of the nucleophile is not protonated, i.e., it is in 
the free base form. Typically, this range is about pH 8.5 
to 11. The selection of condensation over transpeptida 
tion is made kinetically in that transpeptidation is com 
pleted quickly while condensation occurs slowly. In 
particular, transpeptidation occurs between 5 seconds 
and 1.4 hours while condensation occurs between 2 and 
24 hours. 
Transesterification occurs under moderately acidic 
conditions which disfavor hydrolysis. Preferably the 
pH is less than about 6 and greater than about 3. A high 
molar concentration of the alcohol nucleophile is also 
important for transesterification. 
The reaction temperature is the functional range of 
the enzyme, preferably up to about 40' C. 
The concentrations of the reactants and enzyme are 
adjusted to provide optimum results. Generally, the 
highest possible concentrations of enzyme nucleophile 
and protein are used that coincide with an appreciable 
primary coupling reaction rate. Preferably, the protein 
is present at a concentration of from about 1 M to 
about 1M, especially up to about 1 mM when the pro 
tein is an antibody. The nucleophile or intermediate 
incorporating the nucleophile is preferably present at a 
concentration of at least 0.05 molar and especially a 
concentration of from about 0.1 to 2 molar. The enzyme 
is preferably present at a concentration of about 1 pM to 
1 mM. 
The incubation time (reaction time) of the protein and 
the nucleophile is from about 0.2 to 10 hours, preferably 
from 1.0 to 8 hours for condensation while for transpep 
tidation or transesterification, it is from about 30 sec 
onds to about 1.5 hours. 
Specific Embodiments, Antibody Protein 
The pH of the reaction between an antibody and 
nucleophile determines the dominant enzymatic activity 
exhibited by the carboxypeptidase enzymes. Different 
reaction courses are possible at different pH values. The 
incorporation of a nucleophile by condensation, tran 
speptidation or transesterification depends upon which 
reaction course dominates in the incubation mixture. 
At neutral pH values, hydrolysis of peptide bonds (peptidase activity) is generally considered to be the 
dominant activity. As the pH increases, the hydrolysis 
activity decreases and the condensation and transpepti 
dation reactions become the prominent activities of the 
enzyme. When the pH is maintained at a level that pro 
vides the free base form of the nucleophile, typically 
from about 8.5 to 11.0, preferably 9.5, the transpeptida 
tion and condensation reaction are favored with the 
former being kinetically favored (i.e. happens fast). 
Typically, the transpeptidation reaction is preferred 
over condensation because it occurs rapidly in about 30 
seconds to about 1 hour. When the pH is low such as 3.0 
to 6.0 and the molar concentration of alcohol nucleo 
phile is high, transesterification is favored. This reaction 
cleaves the C-terminal amino acid residue of the protein 
and substitutes the alcohol nucleophile by enzyme dis 
placement. 
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In several studies, the pH dependence of amino acid 
nucleophile addition by condensation with an antibody 
was examined and the details are described in the foll 
lowing examples section. The results of these studies, as 
depicted in FIG. 1, show that nucleophile incorporation 5 
is higher at higher temperatures and at higher values of 
pH. At a pH of 7.5, the nucleophile incorporation was 
observed to increase initially, followed by a decrease in 
incorporation and then an additional increase. The first 
incorporation is due to transpeptidation. The decrease 
in incorporation is due to partial loss of the incorpo 
rated nucleophile by the disfavored hydrolysis reaction. 
The second incorporation is due to the slower addition 
of the nucleophile by condensation. 
The effect caused by variation of the concentration of 15 
the reactants in the incubation mixture was also studied 
and the results are shown in Table 2. As generally indi 
cated above, concentration directly affects rate and 
amount of incorporation. The details of the study are 
provided in the following examples section. 
TABLE 2 
Effect on Condensation Reaction 
of Variation of Incubation Conditions 
O 
20 
SER/ 
Time? Abb Serb CPD-Yc Abd 25 
(hrs) (mg/ml) (mM) (im) Ratio Comments 
8 4.1 230 20 3.3 Antibody Conc. 
12.7 234 20 4.7 Varied 
8.8 232 20 1.2 
9 2.3 O 20 0.16 Serine Conc. 
12.3 110 20 0.14 Varied 30 
12.3 220 20 1.34 
12.3 330 20 1.68 
11.5 10.5 122 5 0.14 CPD-Y Conc. 
0.8 112 11 0.15 Varied 
.8 20 6 1.6 
8 7.7 11 20 2.4 No Cosolvent 35 
7.7 175 20 4.2. 30% glycerol 
27 10.5 78 20 0.4 F1-nonoclonal 
11.1 78 20 16.9 F1-polyclonal 
Time of labeling incubation at 37 C., pH 9.5. 
Measured concentration in incubation mixture (Ab = antibody). 
Calculated from concentration of stock solution. 
Molar ratio, determined as described in methods section. The data shows results of 40 
a single representative experiment. Each experiment was repeated several times with 
similar results. 
Measurement made or change from standard method (see text for details). 
The distribution of the nucleophile (labeled amino) 
acid between the carboxy termini of heavy and light 
chains of the antibody was also investigates, and the 
details are given in Example 4. The results indicate that 
the labeled amino acid is preferentially incorporated 
into the heavy chain. At least about 70 percent of the 
incorporated nucleophile is located on the heavy chain. 
Generally, the L-isomers of amino acids are incorpo 
rated by this method, with incorporation occurring 
substantially completely at the carboxyl termini of the 
heavy chains of antibodies. 
Although the light chain of the antibody is labeled by 
this reaction to a certain extent, it is not located near the 
antigen-binding region. Therefore, little effect, if any, 
on the function of the antibody is noted as a result of this 
interaction. 
The antigen-binding capacity of the labeled antibod 
ies as compared to that of the unlabeled antibodies was 
also studied. (See Examples 5 and 6.) For the anti 
asparagine synthetase antibodies the average binding 
capacity was determined to be 100.1 percent of the 
binding capacity with 0.6 serines incorporated per anti 
body. The anti-Flantibodies labeled as in Table 2 were 
also assayed to determine their binding capacity. The 
binding capacity was found to be 105 percent for the 
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monoclonal antibody and 114 percent for the polyclonal 
antibody compared to the unlabeled controls. These 
values are an average of four determinations. The slight 
increases found for the labeled antibodies over the con 
trols are due to experimental errors and are not signifi 
cant. These results show no significant loss of antigen 
binding as a result of label attachment. 
Similar reaction conditions of temperature, pH, and 
concentrations can be established for protein incorpora 
tion of any of the amino acid or amine nucleophiles or 
intermediates as mentioned above. 
Demonstration of Attachment 
The results of some experiments wherein other amino 
acids were used as radioactive labels are shown in Table 
3. The condensation reactions were carried out gener 
ally as described in Example 9 and assayed for label 
incorporation as described in Example 3. The concen 
trations of antibody and amino acid shown in Table 3 
represent actual measured concentrations. The concen 
tration of carboxypeptidase Y is calculated from the 
concentration of the stock solution used. The values of 
label incorporation are given as label incorporated per 
antibody molecule above the value of the control, 
which was incubated under the same conditions with 
out the addition of enzyme. 
TABLE 3 
Condensation to Attach Nucleophile 
Time Abb Label CPD-Ye Label/Abd Labele 
(hrs) (mg/ml) (mM) (uM) Ratio Type 
8.5 8.7 188 20 0.5 Taurine 
8.5 14.6 44 20 1.2 Alanine 
8.5 8.8 232 20 1.2 Serine 
Time of labeling incubation at 37' C., pH 9.5. 
Measured concentration in incubation mixture (Ab = antibody). 
Calculated from concentration of stock solution. 
Molar ratio. 
Amino acid used for labeling reaction. 
Although some quantitative variation in the amount 
of label incorporation was observed in duplicate experi 
ments conditions, this was within experimental error. 
The variation was probably due to the difficulty of the 
separation required for the accurate assessment of the 
label incorporation. High concentrations of unbound 
label were essentially completely and rapidly separated 
from the relatively small quantities of antibody. Some 
Small amount of label, however, apparently remained at 
times, causing quantitative fluctuations in measured 
label incorporation. For this reason, it was necessary to 
include a control sample lacking carboxypeptidase Y 
for each determination. As an added precaution, the 
trailing portion of the antibody peak was not included in 
the quantitation. 
As shown in Table 3, the enzyme incorporates ala 
nine to about the same degree as serine. The enzyme 
was also found to incorporate taurine, an amino acid not 
usually found in proteins. The incorporation of taurine 
was found to be somewhat limited by the solubility of 
the free amino acid, however. 
This method of binding an antibody to a nucleophile 
provides a means of immobilizing, labeling or augment 
ing antibodies without loss of antigen-binding capacity. 
This is due to the primary coupling reaction of the 
nucleophile with the antibody by condensation, tran 
speptidation or transesterification. 
Various nucleophiles can be bound to other func 
tional proteins using similar experimental parameters. 
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The amino acid or amine nucleophile, enzyme, protein, 
and bioactive agent, label or immobilizing support, 
however, are generally chosen so as to enhance specific 
binding and reduce nonspecific binding. In this way, the 
bioactive agent, label or immobilizing support can be 
bound to a protein remote from its functional site. 
The invention will be further characterized by the 
following examples. These examples are not meant to 
limit the scope of the invention that has been set forth in 
the foregoing description. Variation within the con 
cepts of the invention are apparent to those skilled in the 
art. 
Examples 1-8 are standard methods for condensation, 
transpeptidation and transesterification. Example 9 
demonstrates condensation. Examples 10 and 11 dem 
onstrate transpeptidation. Examples 12 and 13 demon 
strate transesterification. 
EXAMPLE 
Antibody Preparation 
Anti-asparagine synthetase monoclonal antibodies 
and anti-F1 ATPase monoclonal and polyclonal anti 
bodies were obtained from laboratory stocks. Mono 
clonal antibody stocks were obtained in the form of 
mouse Ascites tumor fluids and polyclonal antibody 
stocks were obtained from rabbit serum. Antibodies 
from either source were purified by addition of solid 
ammonium sulfate to a concentration of 50% of the 
saturation level. The precipitated protein was collected 
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by centrifugation and dissolved in a minimal amount of 30 
10 mM Tris-HCl (Tris, tris(hydroxymethyl)aminome 
thane(pH 7.5). The preparation was then subjected to a 
second ammonium sulfate treatment until a 50% satura 
tion level was reached. The precipitate was then col 
lected by centrifugation. The purified antibodies were 
dissolved in a minimal amount of water and dialyzed for 
18 to 24 hours against 10 mM sodium bicarbonate at 4 
C. This dialysis step was necessary to remove the resid 
ual ammonium sulfate that was found to inhibit the 
activity of carboxypeptidase Y. The purified antibodies 
were stored in aliquots at -20' C. until needed. 
Unless otherwise noted, these three antibodies were 
used in each of the following examples. The term "anti 
body' as used herein means anti-asparaginine synthe 
tase monoclonal antibody, and anti-Fl ATPase mono 
and polyclonal antibodies. 
EXAMPLE 2 
LABEL PREPARATION 
Serine was used initially as H-serine and in latter 
experiments 1'C-serine was used. All other amino acids 
used were H-amino acids. Radioactive amino acids 
were purchased from Amersham (Arlington Heights, 
IL). Unlabeled serine was from Fluka (Ronkonoma, 
NY). Radioactive amino acids were diluted with unla 
beled amino acid to, a specific activity of 0.5 to 2 mCi 
per millinole. The diluted amino acid was then purified 
by repeated precipitation with ethanol at -20' C. 
These precipitation steps were required to reduce non 
specific binding of the amino acid to the antibodies. The 
anino acid was stored as an aqueous solution at 4 C. 
The specific activity of the diluted, purified amino 
acid was determined as follows, and used in subsequent 
calculations of label incorporation. The quenched, de 
tectible radioactivity was determined under conditions 
identical to those used in the measurement of label in 
corporation. A known volume of the amino acid solu 
tion was diluted to 1.0 ml with 0.1 M sodium phosphate 
35 
45 
55 
65 
26 
(pH 6.8). This diluted sample was counted in a Beckman 
LS-100 liquid scintillation counter (Beckman Instru 
ments, Fullerton, CA) with 10.0 ml 3a70b scintillation 
fluid (Research Products, Elkgrove, IL). The amino 
acid concentration of the stock amino acid solution was 
determined on a known volume by assay of the amino 
groups with the ninhydrin assay; see S. Moore et al., J. 
Biol Chem, 157, 367 (1948). A standard solution was 
prepared for this assay by dissolving glycine in water at 
0' C. to obtain a saturated solution. The liquid was 
separated from any undissolved solid glycine, warmed 
to room temperature, and used as a standard. The con 
centration of the standard was assumed to be 1.89 M; 
see J. B. Dalton et al., J. Biol. Chem, 103, 549 (1933). 
From these measurements, the quenched value of 
CPM/mmole was calculated and used in subsequent 
calculations. 
EXAMPLE 3 
LABEL NCORPORATIONASSAYS 
The unbound amino acids were separated from the 
antibody by gel filtration HPLC. A 20 ul sample of the 
reaction mixture after incubation was applied to a GPC 
300 gel filtration column (Synchrom, Linden, In) and 
eluted with 0.1 M sodium phosphate (pH 6.8). The 
HPLC system employed for this purpose consisted of a 
dual pump gradient system and a variable wavelength 
UV monitor produced by ChemResearch (ISCO, Lin 
coln, NE). The absorbance peak, monitored at 280 nm, 
corresponding to the antibody was collected. In order 
to ensure that complete removal of the unbound amino 
acid from the antibody, only the first of the absor 
bance peak was collected. The collected antibody solu 
tion was diluted to 1 ml with the elution buffer. 
The antibody concentration in the collected solution 
was determined by measurement of the absorbance at 
280 nm, assuming a standard absorbance of 1.46 absor 
bance units/mg. The incorporated amino acid was de 
termined by counting 1.0 ml of the collected antibody 
solution using 10 ml 3a70b liquid scintillation fluid. The 
amount of label incorporated was calculated using the 
corrected specific activity for the amino acid described 
above. The molar concentration of the antibody was 
calculated assuming a molecular weight of 150,000; see 
I. Roitt et al., Inmunology, C. V. Mosby Co., St. Louis, 
p. 5.3 (1985). The reported label incorporation is the 
difference between the values obtained for the samples 
with and without carboxypeptidase Y. The results of 
the label incorporation are discussed in the foregoing 
specific embodiments section in conjunction with FIG. 
2. 
EXAMPLE 4 
ANTIBODY CHAIN SEPARATION 
This example shows the specificity of nucleophile 
coupling to the heavy chain of an antibody as discussed 
in the foregoing specific embodiments section. 
Separation of the heavy and light chains of the anti 
body was performed on both labeled and control (unla 
beled) antibodies. The samples were labeled as de 
scribed above. Following the incubation, the antibodies 
were precipitated by addition of ammonium sulfate to a 
concentration of 50% of saturation. The precipitate was 
collected by centrifugation and the pellet was dissolved 
in a denaturing buffer (pH 6.8) consisting of 100 mM 
sodium sulfate, 2 M urea, 2% sodium lauryl sulfate 
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(SDS), 1% B-mercaptoethanol, and 25 mM 4-morpho 
line ethanesulfonic acid (MES). The sample was incu 
bated at 100' C. for 5 minutes to ensure complete dena 
turation of the protein. The antibody chains were sepa 
rated by gel filtration HPLC using an Altex TSK-125 
column (Biorad, Richmond, CA) equilibrated with the 
denaturing buffer. The effluent was monitored at 280 
nm. The peaks corresponding to the heavy and light 
chains of the antibody were collected separately. The 
collected samples were diluted to 1.2 ml with the dena 
turing buffer. 
The amount of amino acid incorporated into each 
chain was determined by counting 1.0 ml of each sam 
ple with 10 ml 3a70b liquid scintillation fluid. Due to 
interference of the denaturing buffer components the 
amount of protein in each sample could not be deter 
mined by the methods used above or by other com 
monly employed methods. An assay developed for this 
purpose consisted of adding 25 ul of 30% acrylamide, 
0.8% bioacrylamide, to 50 ul of the sample to be as 
sayed. The mixture was polymerized by addition of 1.5 
ul 1 10% ammonium persulfate and 1 ul N,N,N',N' 
tetramethylethylenediamine. The interfering buffer 
components were separated from the solidified sample 
by washing with 2 aliquots (2ml) 10% trichloroacetic 
acid, 3 aliquots (2ml) 10% acetic acid and 3 aliquots 
(2ml) 5% methanol, 7.5% acetic acid. The protein was 
stained with Coomassie Blue R-250 (Commission on 
Biological Stains Number 42660). Following extensive 
washing with 30% methanol, 7.5% acetic acid to re 
move unbound dye, the bound dye was eluted by incu 
bation with SDS, sodium bicarbonate, and methanol. 
The absorbance of the eluted dye was measured and the 
protein content of the sample was determined by com 
parison with standard protein solutions assayed in an 
identical manner. 
The measured protein content and amino acid incor 
poration for each chain were used to calculate the label incorporation per polypeptide chain. In these calcula 
tions, the molecular weights of the heavy and light 
chains were taken to be 50,000 and 25,000, respectively; 
see I. Roitt et al., vide supra. The results based upon the 
data obtained (not shown) are discussed in the forego 
ing specific embodiments section and indicate at least a 
70% incorporation in the heavy chain. 
EXAMPLE 5 
ANT-ASPARAGINE SYNTHETASE 
ANTIBODY IMMUNOPRECIPITATION 
This example shows that the attachment of the nu 
cleophile does not affect the antigen binding capacity of 
the antibody as discussed in the foregoing specific en 
bodiments section. 
Antibodies, both labeled as described above and con 
trols, were assayed by immunoprecipitation to deter 
mine their capacity to bind antigen. An aliquot of the 
incubation mixture was assayed to determine the extent 
of label incorporation. The remainder of the incubation 
mixture (80 ul ) was added to 420 ul of a pancreas 
extract containing asparagine synthetase; see C. A. 
Luehret al., J. Biochem. Biophys. Methods, 3, 151 (1980). 
The pH of the mixture was adjusted to 7.5. Crude pro 
tein A extract (Sigma Chemical Co., St. Louis, MO) 
was washed twice by centrifuging the solution and 
suspending the pellet in 50 mM Tris-HCl (pH 7.5). This 
washed extract was suspended in 5 times its original 
volume of 50 mM Tris-HCl (pH 7.5). After incubation 
of the antibody with the pancreas extract for 18 hours at 
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37 C, 1 ml of crude, washed protein A extract was 
added and incubation was continued for an additional 2 
hours. The mixture was then centrifuged to collect the 
Protein A/antibody/Asparagine Synthetase complex. 
The pellet was washed twice with 50 mM Tris-HCl (pH 
7.5) and then incubated for 2 hours with 200 all of an 
assay solution (pH 7.5) containing 100 mM Tris-HCl, 10 
mM MgCl2, 10 mM ATP, and 10 mM glutamine. The 
solid material was removed by centrifugation and the 
resulting solution was stored at -20 C. for amino acid 
analysis. 
Amino acid analysis was accomplished by HPLC 
separation of the amino acids following derivitization 
with B-mercaptoethanol and o-phthaldialdehyde; see S. 
Unnithan et al., Anal. Biochem, 136, 195 (1984). The 
HPLC system used consisted of a dual pump gradient 
Beckman HPLC system with a Dupont model 836 fluo 
rescence detector (E.I.Dupont, Des Plains, IL) and 
Integrator (Spectra-Physics, Santa Clara, CA). The 
column used was a Rainin Microsorb Cl reversed phase 
column (Rainin Instruments, Woburn, MA). The bind 
ing capacity of the antibodies was assessed by measure 
ment of the hydrolysis of glutamine to glutamate by the 
asparagine synthetase bound to the Protein A/antibody 
complex. The activity of the bound enzyme was deter 
mined by the ratio of the integrated areas of the gluta 
mate and glutamine peaks. The percent activity for the 
labeled antibodies relative to the unlabeled controls was 
calculated from these Glu/Gln ratios. The results gen 
erally indicate that the capacity of antibody with cou 
pled nucleophile is the same as free antibody. See the 
discussion at pages 30 and 31. 
EXAMPLE 6 
ANTI-F1 ATPASE ANTIBODY 
IMMUNOPRECIPITATION 
This example shows the same effect illustrated in 
Example 6. 
Both monoclonal and polyclonal antibodies, labeled 
as described above and unlabeled controls, were as 
sayed by immunoprecipitation to determine their capac 
ity to bind antigen. An aliquot of the incubation mixture 
was assayed to determine the extent of label incorpora 
tion. The remainder of the incubation mixture (80 ul) 
was added 420 ul of a 0.2 mg/ml solution of purified 
bovine F1-ATPase; see A. F. Knowles et al., J. Biol. 
Chem, 247, 6617 (1972). The pH of the reaction mixture 
was adjusted to 7.5. Crude protein A extract was 
washed twice by centrifuging the solution and suspend 
ing the pellet in 50 mM Tris-HCl (pH 7.5). This washed 
extract was suspended in 5 times its original volume of 
50 mM Tris-HCl (pH 7.5). After incubation of the anti 
body with the pancreas extract for 18 hours at 37 C., 1 
ml of crude, washed protein A extract was added and 
incubation was continued for an additional 2 hours. The 
mixture was then centrifuged to collect the Protein 
A/antibody/Fil-ATPase complex. The pellet was 
washed twice with 50 mM Tris-HCl (pH 7.5) and then 
incubated for 2 hours with 100 pull of an assay solution (pH 8.0) consisting of 50 mM N-tris(hydroxymethyl)- 
methylglycine (Tricine), 5 mM MgCl2, and 5 mM 
ATP. The solid material was removed by centrifugation 
and the resulting solution was stored at -20 C. for 
analysis. An additional control lacking antibodies was 
treated similarly. 
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ATPase activity was determined by measurement of 
the released phosphate; see S. Unnithan et al., vide 
supra. The bound enzyme was assessed by the produc 
tion of inorganic phosphate above the value given by 5 
the control which lacked antibody. The percentage of 
binding capacity of the labeled versus unlabeled anti 
bodies was calculated as the ratio of the labeled to the 
unlabeled activities. The results are discussed in the 
specific embodiments section at pages 30 and 31. 
EXAMPLE 7 
STABILITY OF LABELED ANTIBODIES 
The stability of the incorporated label under different 
storage conditions was also determined. For this experi 
ment, label incorporation was assayed on an aliquot of 
the incubation mixture. The antibodies in the remainder 
of the sample were precipitated with ammonium sulfate 
and dissolved in water. An aliquot was stored at 4' C. 
and another at -20' C. for 8 days. Following the stor 
age period the incorporated label in these samples was 
determined and compared to the first sample. The re 
sults are shown in Table 4. 
TABLE 4 
Label Stability 
Conditions Ser/Abb % of t = 0 
t = 0 0.55 100 
8 days, 4' C. 0.63 116 
8 days, -20' C. 0.49 88 
Storage conditions following labeling incubation at 37' C. and pH 9.5. 
Molar ratio, determined as described in methods section, average of two determina 
tons. 
Average percent gain or loss of activity compared to no incubation following 
labelling incubation. 
EXAMPLE 8 
SPECIFICITY OF INCORPORATION 
In order to verify that the incorporation is due to 
catalysis by the enzyme, L-serine at different concentra 
tions and D,L-serine were incorporated by the standard 
method. These results are shown in Table 5. The incor 
poration of D,L-serine is comparable to incorporation 
of L-serine at half the concentration of the D,L-serine. 
If can be explained by the incorporation of only the 
L-isoner. This stereospecificity has been shown for 
carboxypeptidase Yunder other conditions; see R. Hya 
shi et al., J. Biochem, 77, 69 (1975). Nonspecific absorp 
tion or other nonenzymatic means of attachment which 
might occur under these conditions would be expected 
to incorporate both isomers. 
TABLE 5 
Stereospecificity 
Time Abb Serb CPD-Y SER/Abd 
(hrs) (mg/ml) (nM) (tM) Ratio Comments 
8 7.9 198 20 1.7 L-herine 
10.1 26 20 0.9 L-serine 
8.1 177 20 0.5 D,L-serine 
Time of labelling incubation at 37 C. pH 9.5. 
Measured concentration in incubation mixture. 
Calculated from concentration of Stock solution. 
Molar ratio, determined as described in methods section. 
Label used. 
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EXAMPLE 9 
STANDARD CONDITIONS FOR 
ANTIBODY LABELING (CONDENSATION) 
The following conditions and methods for label in 
corporation by condensation were used for all runs 
unless otherwise indicated. A mixture of the antibody 
and amino acid stock solutions was made and diluted 
with water to the desired concentrations. The pH of this 
solution was measured with pH indicator paper (Fisher 
Chemical, Springfield, NJ) and adjusted to 9.5 with 0.5 
M. sodium From this solution a 4 ul portion was re 
moved and diluted to 1.0 ml with 0.1 M sodium phos 
phate (pH 6.8). The absorbance of this solution was 
measured at 280 nm using a Beckman DU-50 spectro 
photometer. The concentration of the antibody in the 
solution was calculated assuming a standard absorbance 
of 1.46 absorbance units per mg of antibody; see A. 
Good et al., in Selected Methods in Cellular Immunology, 
Mishell & Shiigi eds., W. H. Freeman & Co., San Fran 
cisco, p. 284 (1980). The concentration of the amino 
acid in the incubation mixture was determined by 
counting a small sample of the diluted mixture follow 
ing further dilution to 1.0 ml with 0.1 M sodium phos 
phate (pH 6.8). The amino acid concentration was cal 
culated from the counts present using the corrected 
specific activity determined previously and correcting 
for both dilutions, as well as the 5% dilution described 
below. 
The remainder of the undiluted mixture was divided 
into two equal parts. To one of these portions was 
added the carboxypeptidase Y (affinity purified, E.C. 
3.4.16.4, free from endoproteinase contamination) stock 
solution (24.3 mg-m/1) at 5 ul per 100 ul of mixture. 
The other portion served as a control and was diluted 
similarly with water. Once these two solutions were 
prepared, they were incubated in a 37' C. water bath for 
approximately 8 hours. The samples were then removed 
from the water bath and either analyzed immediately or 
frozen and used as soon as possible. The results of the 
variation in concentration of the label are provided in 
foregoing Table 2 and discussed in conjunction there 
with. 
EXAMPLE 10 
TRANSPEPTIDATION WITH A 
TETRAPEPTIDE MODEL 
This example illustrates the synthesis of the tetrapep 
tide Benzoyl-Thr-Val-Ser-(14C)Ser from Benxoyl-Thr 
Val-Ser-Ser. About 5 to 10 mM of Benzoyl-Thr-Val 
Ser-Ser (BTVSS) may be dissolved in 2 ml of 50 nM 
sodium carbonate buffer (pH 9.5) containing 1 mM 
EDTA and 0.25 M 14-C-serine. The reaction may be initiated by the addition of 5 uM carboxypeptidase Y 
enzyme. At preset time intervals, the reaction may be 
sampled by removing 0.2 ml aliquots and diluting with 
0.2 ml of acetonitrile, then adding 0.1 ml of 0.12 M 
acetic acid. 
The samples may then be subjected to high pressure 
liquid chromatography (HPLC) using a reverse phase 
C-18 column developed with a linear gradient con 
structed from two solvents. A first solvent (A) can be 
95% of 10 mM sodium acetate, 5% acetonitrile pH 4.5 
and the second (B) can be 60% acetonitrile. A gradient 
can be developed over a 30 min time period and can be 
initiated by mixing solvents A and B at the proportions 
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of 1 part A and 0 parts B and ended with 40 parts A and 
60 parts B. The flow rate can be maintained at 1.0ml per 
min. The peptide should elute and be free of serine and 
BTVS (hydrolyzed BTVSS). 
Separate amino acid analyses of the HPLC fraction 
should show the peptide to contain one residue each of 
Thr, Val and two residues of Ser. The specific activity 
of both the serine recovered from amino acid analysis 
and that of the peptide should be the same on a molar 
basis. 
EXAMPLE 11 
TRANSPEPTIDATION WITH A 
TETRAPEPTIDE MODEL 
This example illustrates the synthesis of the tetrapep 
tide Benzoyl-Gly-Ala-Pro-Phe-NH: from Benzoyl-Gly 
Ala-Pro-Ala. About 10 ul of 100 mM of Benzoyl-Gly 
Ala-Pro-Ala-OH (BGAPA) in dimethyl phthalate 
(DMP) may be combined with 19.11 g/ul of 70 mM 
L-phenylalanine amide in 5 mM EDTA (pH 6.5). The 
reaction may be initiated by the addition of 15ul of 22 
mg/ml carboxypeptidase Yenzyme (CPD-Y). At preset 
time intervals, the reaction may be sampled by remov 
ing 10 ul aliquots and diluting with 200 ul of acetoni 
trile. Aliquots may be taken at the following approxi 
mate times: time 0 (prior to adding the enzyme), 1 min 
ute, 5 minutes, 10 minutes, 20 minutes, 40 minutes, 1 
hour, 2 hours, and 3 hours. 
The samples may then be subjected to high pressure 
liquid chromatography (HPLC) using a reverse phase 
C-18 column developed with a linear gradient con 
structed from two solvents. A first solvent (A) can be 
90% of 50 mM triethylamine phosphate (TEAP) (pH3) 
with 10% acetonitrile, and the second solvent (B) can 
be 80% acetonitrile with 20% solvent A. TEAP may be 
prepared by titrating 50 mM phosphoric acid with dis 
tilled triethylamine to pH 3. A gradient can be devel 
oped over a 5 minute time period and can be initiated by 
mixing solvents A and B at the proportions of 1 part A 
and 0 part B and ended with 40 parts A and 60 parts B. 
The flow rate can be maintained at 1.5 ml per min. The 
BGAPA should disappear with the concommittant 
appearance of BGAPP-amide product and free alanine. 
The peptide should elute and be free of phenylalanine 
amide, BGAPA, and Ala. 
Separate amino acid analyses of the HPLC fraction 
should show the peptide to contain one residue each of 
Benzoyl, Gly, Ala, Pro, and Phe. The specific activity 
of both the phenylalanine amide recovered from amino 
acid analysis and the phenylalanine amide in the peptide 
should be the same on a molar basis. 
EXAMPLE 12 
TRANSPEPTIDATION WITH 
ANTI-ASPARAGINE 
SYNTHETASE MONOCLONAL ANTIBODY 
This example illustrates the synthesis of C-Nor-C- (14C)Ser anti-asparagine synthetase monoclonal anti 
body (Nor-Mab-Ser') from anti-asparagine synthetase 
monoclonal antibody (Mab). About 0.2 mM of Mab 
may be dissolved in 2 ml of 50 mM sodium carbonate 
buffer (pH 9.5) containing 1 mM EDTA and 0.25 M 
14-C-serine. The reaction may be initiated by the addi 
tion of 5 M of carboxypeptidase Y enzyme. At preset 
time intervals, the reaction may be sampled by remov 
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ing 0.2 ml aliquots and diluting with 0.2 ml of acetoni 
trile, then adding 0.1 ml of 0.12 Macetic acid. 
The samples may then be subjected to high pressure 
liquid chromatography (HPLC) using a reverse phase 
C-18 column developed with a linear gradient con 
structed from two solvents. A first solvent (A) can be 
95% of 10 mM sodium acetate, 5% acetonitrile pH 4.5 
and the second (B) can be 60% acetonitrile. A gradient 
can be developed over a 30 min time period and can be 
initiated by mixing solvents A and B at the proportions 
of 1 part A and 0 parts B and ended with 40 parts A and 
60 parts B. The flow rate can be maintained at 1.0 ml per 
min. The Nor-Mab-Ser should elute and be free of ser 
ine and Mab. Separate amino acid analysis should show 
the Nor-Mab-Ser to contain one residue of Ser. The 
specific activity of both the serine recovered from 
amino acid analysis and that of the Nor-Mab-Ser' 
should be the same on a molar basis, 
EXAMPLE 13 
TRANSESTERIFICATION USINGA 
TETRAPEPTIDE MODEL 
This example illustrates the synthesis of Benzoyl-Thr 
Val-Ser-(14 C)OMe from Benzoyl-Thr-Val-Ser-Ser. 
About 5 to 10 mM of Benzoyl-Thr-Val-Ser-Ser 
(BTVSS) may be dissolved in 2 ml of 50 mM sodium 
phosphate/phosphoric acid buffer (pH 3.5) containing 1 
mM EDTA and 0.25 M 14C-methanol (MeOH). The 
reaction may be initiated by the addition of 5 M of 
carboxypeptidase Y enzyme. At preset time intervals, 
the reaction may be sampled by removing 0.2 ml ali 
quots and diluting with 0.2 ml of acetonitrile, then add 
ing 0.1 ml of 0.12 Macetic acid. 
The samples may then be subjected to high pressure 
liquid chromatography (HPLC) using a reverse phase 
C-18 column developed with a linear gradient con 
structed from two solvents. A first solvent (A) can be 
95% of 10 mM sodium acetate, 5% acetonitrile pH 4.5 
and the second (B) can be 60% acetonitrile. A gradient 
can be developed over a 30 min time period and can be 
initiated by mixing solvents A and B at the proportions 
of 1 part A and 0 parts B and ended with 40 parts A and 
60 parts B. The flow rate can be maintained at 1.0ml per 
. 
The peptide should elute and be free of methanol and 
BTVS (hydrolyzed BTVSS). Separate amino acid anal 
ysis should show the peptide to contain one residue 
each of Thr, Val and a Ser methyl ester. The specific 
activity of both the serine methyl ester recovered from 
amino acid analysis and that of the peptide should be the 
same on a molar basis. 
EXAMPLE 14 
TRANSESTEREFICATION USING 
ANTI-ASPARAGINE 
SYNTHETASE MONOCLONAL ANTIBODY 
This example illustrates the synthesis of 14C methyl 
C-nor-Anti-asparagine synthetase monoclonal antibody 
ester ("methyl-Nor-Mab) from anti-asparagine synthe 
tase monoclonal antibody (Mab). About 0.2 mM of Mab 
may be dissolved in 2 ml of 50 mM sodium phosphate/- 
phosphoric acid buffer (pH 3.5) containing 1 mM 
EDTA and 0.25 M 14-C-Methanol. The reaction may 
be initiated by the addition of 5M of carboxypeptidase 
Y enzyme. At preset time intervals, the reaction may be 
sampled by removing 0.2 ml aliquots and diluting with 
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0.2 ml of acetonitrile, then adding 0.1 ml of 0.12 M 
acetic acid. 
The samples may then be subjected to high pressure 
liquid chromatography (HPLC) using a reverse phase 
C-18 column developed column developed with a linear 
gradient constructed from two solvents. A first solvent 
(A) can be 95% of 10 mM sodium acetate, 5% acetoni 
trile pH 4.5 and the second (B) can be 60% acetonitrile. 
A gradient can be developed over a 30 min time period 
and can be initiated by mixing solvents A and B at the 
proportions of 1 part A and 0 parts B and ended with 40 
parts A and 60 parts B. The flow rate can be maintained 
at 1.0 ml per min. The 'methyl-Nor-Mab should elute 
and be free of methyl and Nor-Mab (hydrolyzed Mab). 
Separate amino acid analysis should show the "methyl 
Nor-Mab to contain one residue of methyl serine ester. 
The specific activity of both the methyl serine ester 
recovered from amino acid analysis and that of the 
methyl-Nor-Mab should be the same on a molar basis. 
We claim: 
1. A method for forming a protein bound to an auxil 
iary substance, comprising: 
coupling a nucleophile to a protein having a C-ter 
minus amino acid with the C-terminus as a carbox 
ylic acid group, and an amino acid having a car 
bonyl group penultimate to the C-terminus amino 
acid by catalysis at acidic or basic pH with an exo 
peptidase enzyme to form an adduct, wherein the 
nucleophile is an amino acid derivative having an 
amine group and a side chain with a distinctive 
reactive substituent, and the coupling is between 
the amine group of the nucleophile and the C-ter 
minus carboxylic acid group of the protein or the 
carbonyl group of the amino acid penultimate to 
the C-terminus of the protein; and, 
binding the adduct to the auxiliary substance or its 
combination with a linker arm to form the bound 
protein, wherein the auxiliary substance or combi 
nation has a specifically reactive group that is cor 
relatively reactive toward the distinctive reactive 
substituent of the adduct, and the specifically reac 
tive group and the distinctive reactive substituent 
react with each other without substantially involv 
ing other groups of the protein to accomplish the 
binding; and 
wherein the bound protein is a straight chain of the 
protein, nucleophile and auxiliary substance 
bonded together or a straight chain of the protein, 
nucleophile, linker and auxiliary substance bonded 
together, and only two sites on each of the nucleo 
phile and linker as well as only one site on each of 
the protein and auxiliary substance are chain bind 
ing sites. 
2. A method for forming a protein bound to an auxil iary substance, comprising: 
binding a nucleophile to the auxiliary substance or its 
combination with a linker arm to form an interme 
diate, wherein the nucleophile is an amino acid 
derivative having an amine group or an alcohol 
group and with a reactive substituent and the auxil 
iary substance or combination has a reactive group 
that is reactive toward the reactive substituent of 
the nucleophile, and the binding is between the 
reactive substituent and the reactive group; and 
coupling the intermediate to a protein having a C-ter 
minus amino acid with the C-terminus as a carbon 
ylic acid group, and an amino acid having a car 
boxyl group penultimate to the C-terminus amino 
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acid by catalysis at acidic or basic pH with an exo 
peptidase enzyme to form the bound protein, the 
coupling reaction being between the amine or alco 
hol group of the nucleophile within the internedi 
ate and the C-terminus carboxylic acid group of the 
protein or the carbonyl group of the amino acid 
residue penultimate to the C-terminus of the pro 
tein; and 
wherein the bound protein is a straight chain of the 
protein, nucleophile and auxiliary substance 
bonded together or a straight chain of the protein, 
nucleophile, linker and auxiliary substance, and 
only two sites on each of the nucleophile and linker 
as well as only one site on each of the protein and 
auxiliary substance are chain binding sites. 
3. A method for preparing a labeled protein, compris 
ling: 
coupling a nucleophile and a protein having a C-ter 
minus amino acid with the C-terminus as a carbox 
ylic acid group, and an 1) amino acid penultimate 
to the C-terminus amino acid having a carboxy 
group in a medium at acidic or basic pH and in the 
presence of an exopeptidase enzyme to form an 
adduct, said nucleophile being an amino acid, 
amino acid derivative, amine or 1) alcohol having 
an amine group or an alcohol group and a side 
chain with a distinctive reactive substituent se 
lected from the group consisting of sulfhydryl, 
hydroxyl, activated hydroxyl, olefinyl, activated 
ester, amino, azidyl, hydrazinyl, phosphoramidoyl, 
boronyl, ferrocenyl, ferro complexes and mixtures 
thereof, wherein the concentration of said enzyme 
is from about 1 pM to 1 mM, and the coupling is 
between the amine or alcohol group of the nucleo 
phile within the adduct and the C-terminus carbox 
ylic acid group of the protein or the carbonyl 
group of the amino acid penultimate to the C-ter 
minus of the protein; 
combining a label and a linker arm to form a combina 
tion, said label being fluoroescent, nuclear mag 
netic, phosphorescent, colorimetric, magnetic, 
electron resonant or spectrometric and having at 
least one reactive group, said linker arm being a 
flexible or semi-flexible chain having a specifically 
reactive group that is correlatively reactive with 
the distinctive reactive substituent and another 
functional group that is reactive toward the reac 
tive group of the label, and the combining being 
between the reactive group of the label and the 
functional group of the linker arm; and 
binding the adduct and the combination to form the 
labeled protein, the binding being between the 
distinctive reactive substituent and the specifically 
reactive group; wherein, 
the correlative reactivity of the specifically reactive 
group and the distinctive reactive substituent result 
in their reaction with each other without substan 
tially involving other groups of the protein; and 
wherein the labeled protein is a straight chain of the 
protein, nucleophile, linker and label bonded to 
gether, and only two sites on each of the nucleo 
phile and linker as well as only one site on each of 
the protein and label are chain binding sites. 
4. A method for preparing a labeled protein, compris 
1ng: 
combining a label and a linker arm to form a combina 
tion, said label being fluorescent, nuclear magnetic, 
phosphorescent, colorimetric or spectrometric and 
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having at least one combining group, and said 
linker arm being a flexible or semi-flexible chain 
having a specifically reactive group that is or is 
rendered non-reactive with the combining group of 
the label and another functional group that is reac- 5 
tive toward the combining group of the label, and 
the combining is between the combining group of 
the label and the functional group of the linker arm; 
binding the combination and a nucleophile to form an 
intermediate, said nucleophile being an amino acid, 
amino acid derivative, amine or alcohol having an 
amine group or an alcohol group and a side chain 
with a distinctive reactive substituent that is reac 
tive toward the specifically reactive group of the 
combination, and the binding being between the 
distinctive reactive substituent and the specifically 
reactive group; and 
coupling the intermediate and a protein having a 
C-terminus amino acid having a carbonyl group 
with the C-terminus as a carboxylic acid group, 
and an amino acid penultimate to the C-terminus 
amino acid in a medium at acidic or basic pH and in 
the presence of an exopeptidase enzyme to form 
the labeled protein, wherein the concentration of 
the enzyme is from about 1 pm to 1 mM, and the 25 
coupling is between the amino or alcohol group of 
the nucleophile within the intermediate and the 
C-terminus carboxylic acid group of the protein or 
the carbonyl group of the amino acid penultimate 
to the C-terminus of the protein; and 
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wherein the labeled protein is a straight chain of the 
protein, nucleophile, linker and label bonded to 
gether, and only two sites on each of the nucleo 
phile and linker as well as only one site on each of 
the protein and label are chain binding sites. 
5. A method according to claim 3 or 4 wherein the 
coupling conditions are basic and the nucleophile is an 
amino acid, amino acid derivative or amine, and the 
reaction is conducted for at least about 5 seconds. 
6. A method according to claim 3 or 4 wherein the 
protein, nucleophile and enzyme are combined in an 
aqueous mixture, wherein the aqueous mixture is 
formed by: 
(a) combining the protein and the nucleophile to form 
a mixture; (b) adjusting the pH of the mixture to within a range 
of about 2.0 to 10.5; and 
(c) adding the enzyme to the mixture. 
7. A method according to claim 3 or 4 wherein the 
reaction between the distinctive reactive substituent 
and the specifically reactive group is a non-competitive 
reaction which does not involve other functional 
groups of the protein or a competitive reaction which is 
controlled to provide substantially selective reaction 
between the specifically reactive group and distinctive 
reactive substituent relative to the reaction of either of 
the specifically reactive group and the distinctive reac 
tive substituent with other functional groups of the protein. 
S K it is 
